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progression and bevacizumab 7.5 mg/kg was administered until progression. The 
model estimated average survival, PFS, drug and administration costs and total costs 
per patient treated with BCG or CVC. RESULTS: BCG treatment results in a mean 
survival of 1.51 years versus 1.38 years with CVC. Both drug and administration costs 
were lower with BCG than CVC and the mean total cost per patient treated with BCG 
was less costly than CVC (a33,153 versus a40,700, respectively). CONCLUSIONS: 
BCG, compared with CVC, gives a greater clinical beneﬁt and is less costly. Therefore, 
BCG is dominant over CVC and should be considered to be therapy of choice for 
treating patients with advanced NSCLC.
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OBJECTIVES: Implemented in several countries, biennial Guaiac Fecal Occult Blood 
Test (FOBT) is used as mass screening for Colorectal Cancer. Using Guaiac FOBT as 
the reference strategy, we estimated the cost-effectiveness of three screening alterna-
tives: biennial Immunological FOBT, Computed Tomography Colonoscopy every 5     
and 10 years (respectively CTC-5 and CTC-10). METHODS: Over a 30-year horizon 
and from the perspective of a third-party payer, we developed a partially observed 
Markov model on a hypothetical cohort of 100,000 subjects at average risk for 
colorectal cancer. Costs were based on French data. Epidemiological parameters were 
from the international literature. The incremental net beneﬁt framework was used to 
describe our results. Then, we performed univariate and probabilistic sensitivity analy-
ses. RESULTS: Compared with Guaiac test strategy, each alternative led to an increase         
in both discounted costs and life-years gained (LYG). The optimal strategy was       
 function of the willingness to pay (WTP). Immunological FOBT resulted in lower   
prevention rate (14%) than CTC-5 (38%) or CTC-10 (24%). However, the two-year 
frequency of Immunological FOBT enabled an earlier detection of cancers conducing 
to higher number of LYG than CTC-10. Outcomes were sensitive to adherence rates.       
Probabilistic sensibility analysis suggested that below a WTP of 1,807a/LYG, the refer-
ence strategy was optimal whilst CTC-10 was preferred between a1807 and a8124 /
LYG. Beyond a WTP of a8124/LYG, CTC-5 provided the highest incremental net 
beneﬁt. Although, Immunological FOBT was subject to extended dominance, it was 
still optimal for one third of the simulations for a WTP between a15,000 and 
a120,000/LYG. This result was due to close expected net beneﬁts between Immuno-
logical FOBT and CTC-5 and induced uncertainty in the choice of the optimal strat-
egy. CONCLUSIONS: From a reasonable willingness to pay of the third-party payer, 
Guaiac FOBT strategy was no longer optimal for colorectal cancer mass screening.
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OBJECTIVES: An economic model was constructed to assess the cost effectiveness of           
docetaxel/cyclophosphamide (TC) compared with doxorubicin/cyclophosphamide 
(AC) as adjuvant treatment for women with operable breast cancer. An Australian 
government perspective was adopted for the analysis. METHODS: A cost utility   
analysis was undertaken for a model population of women with operable breast 
cancer. The median age at baseline was 51 years. Four cycles of docetaxel (75 mg/m 2) 
plus cyclophosphamide (600 mg/m 2) were compared to four cycles of doxorubicin 
(60 mg/m 2) plus cyclophosphamide (600 mg/m 2). Seven year overall survival and 
disease free survival results were utilised from a pivotal randomised control trial (Jones 
et al, 2009). Overall survival was extrapolated to a 35 year model horizon. Utility 
weights were derived from a valuation study conducted in an Australian general 
population sample. Expert opinion garnered from a treatment practice survey of 
clinicians informed the average frequency and type of resources required for diagnosis 
and treatment of recurrence of disease. RESULTS: Adjuvant treatment of operable    
breast cancer with TC was associated with incremental costs of A$6253, and 
incremental QALYs (Quality Adjusted Life Years) of 0.48 (at 35 years) when compared 
to AC. The incremental cost–effectiveness ratio was estimated at approximately 
A$13,000 per QALY when assessed at 35 years. CONCLUSIONS: We found TC to    
be a highly cost effective intervention as adjuvant treatment of operable breast cancer 
when compared with AC in the Australian setting.
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OBJECTIVES: To develop a cost-effectiveness analysis to compare docetaxel vs 
docetaxeltrastuzumab as ﬁrst line therapy in the treatment of patients with advanced 
or metastatic breast cancer HERneu from the public health system Perspective in 
Mexico. METHODS: A markov model was built in order to simulate the clinic course 
of a cohort of patients with metastatic breast cancer HERneu in treatment with 
docetaxel vs docetaxeltrastuzumab as ﬁrst line treatment. The model include 
three health states (without progression, progression and death), with a 12- month 
following. Conceptual frame and clinical course was based on literature review and 
controlled clinical trials. In order to deﬁne resources and procedures to set costs, a 
literature search for economic evaluation and different disease management alterna-
tives was done. The drugs costs were obtained from the costs of purchasing published 
by the Mexican Institute of Social Security and included diagnosis, treatment, follow-
ing and medical support. The clinical beneﬁt of the treatment is to be determined by 
Progression-Free Survival (PFS). RESULTS: Using docetaxeltrastuzumab 49.1% of 
patients were free of progression and 25.6% of those who used only docetaxel during 
the 12 months of management; In other words, to maintain a patient free of progres-
sion at 12 moths is necessary to treat 2.04 and 3.91 patients with docetaxeltrastuzumab 
and docetaxel respectively. The expected cost with docetaxeltrastuzumab is 
US$32,460.87 and with docetaxel US$22,735.74. The cost to maintain a patient free 
of progression at 12 moths is US$66,085.92 and US$88,899.50 (mean cost effective-
ness ratio) and the ICER is US$41,305. CONCLUSIONS: Results show that 
docetaxeltrastuzumab is a cost effective therapy when comparing with docetaxel in 
ﬁrst line therapy for patients with metastatic breast cancer.
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OBJECTIVES: Because of an unfavorable health economics assessment commissioned 
by the Ministry of Health, in Austria HPV vaccination costs are not covered by the 
government. We have performed an additional assessment based on essentially the 
same cost data and only slightly different assumptions concerning infection and disease 
propagation but simulating cohorts for their whole life expectancy. METHODS: The 
applied model is of a hybrid type. The dynamic infection model was formulated as a 
SIR model with delayed transition from the recovered state into the susceptible state. 
It was validated by comparison with empirical infection rates for the different HPV 
strains within age groups. Vaccination of 85% of 12 year old girls was modeled. Two 
equally sized cohorts of girls were followed from birth to 100 years of life, one vacci-
nated against HPV types 16 and 18 and one unvaccinated, both were assumed to have 
unchanged opportunistic screening. All estimates were based on 1000 runs of these 
cohorts. The infection model was validated by comparison of the unvaccinated cohort 
with the Austrian incidence and mortality data for the years 2002 to 2007. RESULTS: 
Vaccination of 85% of 12 year old girls resulted in a decrease of mortality by 64% and 
incidence by 69%. Cervical intraepithelial neoplasias (CIN) were reduced too: 27%, 
46% and 49% for CIN1 to CIN3, respectively. Without discounting vaccination was 
cost saving. Assuming discount rates between 2 and 6% the incremental cost-effective-
ness ratio (ICER) was 6,000.- to 21,000.- a/LYG. Sensitivity analyses demonstrate that, 
except for discount rates, a booster vaccination and no cross-protection against 
non-vaccine types has the greatest inﬂuence on ICER. CONCLUSIONS: Also for the 
Austrian health care system vaccination is cost-effective in the long run, although it’s 
full economic impact is—concerning cervical cancer—seen only after decades.
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OBJECTIVES: To estimate the cost-effectiveness of docetaxel for breast cancer treat-
ment in adjuvant and metastatic settings. Three comparisons are performed: 3 cycles 
of ﬂuorouracil, epirubicin and cyclosphophamide followed for 3 cycles of docetaxel 
(3FEC100-3D) versus 6 cycles of ﬂuorouracil, epirubicin and cyclosphophamide 
(6FEC100); 6 cycles of ﬂuorouracil, doxorubicin and cyclosphophamide (FAC) versus 
6 cycles of docetaxel, doxorubicin and cyclosphophamide (TAC), both as adjuvant 
treatments; and docetaxel versus paclitaxel in metastatic breast cancer (MBC). 
METHODS: The lifetime Markov model used for the adjuvant setting analysis, 
developed by Aremis Consultants, considers 6-month cycles and 4 health states: no 
recurrence; loco-regional recurrence; metastatic recurrence; and death. The model for 
MBC, created by United Bio Source, lasts for 10 years with 3-week cycles and 3 health 
states: no progression; progression; and death. Transition probabilities were derived 
from head-to-head clinical trials. Direct medical costs were estimated for the Society 
and the tertiary cancer centre Instituto Português de Oncologia de Lisboa (IPOL) 
perspectives. Resource consumption was based on clinical practice at IPOL (patient-
level data). Unit costs were derived from ofﬁcial sources and IPOL data. RESULTS: 
The projected survival advantage was 0.93 years for TAC compared to FAC, with an 
incremental cost of a8369 for the Society and a8031 for IPOL, and 0.49 years for 
3FEC100-3D compared to 6FEC100, with incremental costs below a3700 for either 
perspective. In both cases, incremental costs per life year gained (ICER) are below 
a9000. In MBC, the predicted incremental life expectancy with Docetaxel is 6 months, 
being the incremental cost of around a11,000 for either Society or IPOL. The ICER 
is a21,905 and a22,329, respectively. Sensitivity analysis shows that these ﬁndings are 
only responsive to changes in the relative clinical gains of docetaxel. CONCLUSIONS: 
